Expression of p21WAF1/CIP1 is unrelated to p53 tumour suppressor gene status in oral squamous cell carcinomas

Oral Oncology

Volumn 34, Issue 3, 1998, Pages 198-203

  Yook, J I ^a   J, Kim ^a  

^a Yonsei University   (South Korea)

Author keywords

Immunohistochemistry; Mutation; Oral squamous cell carcinomas; Overexpression; P21WAF1 CIP1; P53 tumour suppressor gene; PCR SSCP

Indexed keywords

PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MOUTH CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; FEMALE; GENES, P53; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MUTATION; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032078740     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(97)00091-2     Document Type: Article

References (40)

1. [1] Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
2. [2] Zambetti GP, Levine AJ. A comparision of the biological activities of wild-type and mutant p53. FASEB 1993;7:855-865.
3. [3] El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
4. [4] Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C. Wild-type p53 activates transcription in vitro. Nature 1992;358: 83-86.
5. [5] Dulic V, Kaufmann WK, Wilson SJ, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994;76:1013-1023.
6. [6] Li Y, Jenkins CW, Nichols MA, Xiong Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 1994;9:2261-2268.
7. [7] Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;369:574-578.
8. [8] Skapek SX, Rhee J, Spicer DB, Lassar AB. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 1995;267:1022-1024.
9. [9] El-Deiry WS, Tokino T, Waldman T, et al. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Research 1995;55:2910-2919.
10. [10] Field JK, Pavelic ZP, Spandidos DA, Stambrook PJ, Jones AS, Gluckman JL. The role of the p53 tumor suppressor gene in squamous cell carcinoma of the head and neck. Archives of Otolaryngology Head and Neck Surgery 1993;119:1118-1122.
11. [11] Sakai E, Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 1992;7:927-933.
12. [12] Somers KD, Merrick MA, Lopez ME, Incognito LA, Schechter GL, Casey G. Frequent p53 mutations in head and neck cancer. Cancer Research 1992;52:5997-6000.
13. [13] Beahrs OH, editor. Manual for Staging of Cancer, 3rd Edition. Philadelphia: JB Lippincott, 1988.
14. [14] Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP. A variation in the structure of the protein-coding region of the human p53 gene. Gene 1988;70:245-252.
15. [15] Orita M, Iwahana H, Kanazawa H, Kayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proceedings of the National Academy of Science, USA 1989;86:2766-2770.
16. [16] Hongyo T, Buzard GS, Calvert RJ, Weghorst CM. "Cold SSCP": a simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses. Nucleic Acids Research 1993;21:3637-3642.
17. [17] Yaginuma Y, Westphal H. Analysis of the p53 gene in human uterine carcinoma cell lines. Cancer Research 1991;51:6506-6509.
18. [18] DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. American Journal of Pathology 1995;147:884-888.
19. [19] Bass IO, Mulder JWR, Offerhous JA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. Journal of Pathology 1994;172:5-12.
20. [20] Beenken SW, Karsenty G, Raycroft L, Lozano G. An intron binding protein is required for transformation ability of p53. Nucleic Acid Research 1991;19:4747-4752.
21. [21] Barnes DM, Hanby AM, Gillett CE, et al. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 1992;340:259-263.
22. [22] Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69: 1237-1245.
23. [23] Chen J, Wu X, Lin J, Levine AJ. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Molecular and Cellular Biology 1996;16:2445-2452.
24. [24] Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-1136.
25. [25] Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-816.
26. [26] Marchetti A, Doglioni C, Barbareshi M, et al. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 1996;12:1319-1324.
27. [27] Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-indepedent pathway. Cancer Research 1994;54:3391-3395.
28. [28] Matsuta M, Kon S, Sasaki K, Matsuta M. Immunohistochemical detection of p21WAF1/CIP1 and p53 proteins in formalin-fixed paraffin-embedded tissue sections of squamous cell carcinoma of the skin. Journal of Dermatological Science 1997;14:233-239.
29. [29] Sasaki K, Sato T, Kursoe A, Ikeda E. Immunohistochemical detection of p21waf1/cip1/sdi1 and p53 proteins in formalin-fixed, paraffin-embedded tissue sections of colorectal carcinoma. Human Pathology 1996;27:912-916.
30. [30] Shiohara M, El-Deiry WS, Wada M, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994;11:3781-3784.
31. ser→arg polymorphism of the WAF-1/CIP-1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): the polymorphism distinguishes Caucasians from Chinese. Cancer Epidemiology and Biomarkers Prevention 1995;4:261-267.
32. [32] Li YJ, Laurent-Puig P, Salmon RJ, Thomas G, Hamelin R. Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene 1995;10:599-601.
33. [33] Gudas J, Nhuyen H, Li T, Hill D, Cowan KH. Effects of cell cycle, wild-type p53 and DNA damage on p21CIP1/WAF1 expression in human breast epithelial cells. Oncogene 1995;11:253-261.
34. [34] Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proceedings of the National Academy of Science, USA 1995;92: 5545-5549.
35. [35] Upadhyay S, Li G, Liu H, Chen YQ, Sarkar FH, Kim HRC. bcl-2 suppresses expression of p21WAF1/CIP1 expression of p21WAF1/CIP1 in breast epithelial cells. Cancer Research 1995; 55:4520-4524.
36. [36] Barboule N, Mazars P, Baldin V, et al. Expression of p21WAF1/ CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. International Journal of Cancer 1995;63:611-615.
37. [37] Xiong Y, Zhang H, Beach D. Subunit rearragement of the cyclin-dependent kinases is associated with cellular transformation. Genes and Development 1993;7:1572-1583.
38. [38] Zhang H, Hannon GJ, Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes and Development 1994;8:1750-1758.
39. [39] Chang SE, Foster S, Betts D, Marnock WE. DOK a cell line established from human dysplastic oral mucosa, shows a partially transformed non-malignant phenotype. International Journal of Cancer 1992;52:896-902.
40. [40] Warnakulasuriya KAAS, Johnson NW. Expression of p53 mutant nuclear phosphoprotein in oral carcinoma and potentially malignant oral lesions. Journal of Oral Pathology and Medicine 1992;21:404-408.